S
Shanti Natarajan-Amé
Researcher at University of Strasbourg
Publications - 23
Citations - 1118
Shanti Natarajan-Amé is an academic researcher from University of Strasbourg. The author has contributed to research in topics: Aspergillosis & Amphotericin B. The author has an hindex of 12, co-authored 21 publications receiving 1023 citations.
Papers
More filters
Journal ArticleDOI
Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients.
Raoul Herbrecht,Valérie Letscher-Bru,Corina Oprea,Bruno Lioure,J. Waller,Odile Villard,Kun-Lun Liu,Shanti Natarajan-Amé,Patrick Lutz,Patrick Dufour,Jean-Pierre Bergerat,Ermanno Candolfi +11 more
TL;DR: Galactomannan ELISA seems less sensitive than previously described, and sensitivity can be further reduced by the presence of anti-Aspergillus antibodies.
Journal ArticleDOI
Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis
Yasmine Nivoix,Michel Velten,Valérie Letscher-Bru,Alireza Moghaddam,Shanti Natarajan-Amé,Cécile Fohrer,Bruno Lioure,Karin Bilger,Philippe Lutun,Luc Marcellin,Anne Launoy,Guy Freys,Jean-Pierre Bergerat,Raoul Herbrecht +13 more
TL;DR: Kohno et al. as discussed by the authors retrospectively reviewed 385 cases of suspected or documented aspergillosis that occurred during a 9-year period and identified 289 episodes that fulfilled the criteria for possible, probable, or proven invasive Aspergillus active antifungal drug treatment.
Journal ArticleDOI
The lipid formulations of amphotericin B.
TL;DR: Liposomal amphotericin B is also indicated for empirical therapy of suspected fungal infections in febrile neutropenic patients giving this compound an advantage over the two other formulations.
Journal ArticleDOI
Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B.
Raoul Herbrecht,Valérie Letscher-Bru,Cécile Fohrer,F. Campos,Shanti Natarajan-Amé,Alina Zamfir,J. Waller +6 more
TL;DR: Change of treatment to posaconazole given orally at 200 mg four times/d resulted in progressive improvement leading to cure leading finally to cure after 24 weeks of therapy.
Journal ArticleDOI
Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen
Cécile Fohrer,Sophie Caillard,Argyro Koumarianou,Bernard Ellero,Marie Lorraine Woehl-Jaegle,Carole Meyer,Eric Epailly,Marie-Pierre Chenard,Bruno Lioure,Shanti Natarajan-Amé,Frédéric Maloisel,Philippe Lutun,Romain Kessler,Bruno Moulin,Jean-Pierre Bergerat,Philippe Wolf,Raoul Herbrecht +16 more
TL;DR: It is demonstrated that an individual dose‐adjustment of ACVBP regimen was manageable in PTLD patients and favourably impacted on long‐term survival.